Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V940 plus BCG versus BCG alone in high-risk non-muscle invasive bladder cancer
2024-517335-46-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 19
01
Overview
Phase 2, randomised, open-label trial in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) comparing V940 + BCG with BCG monotherapy (2 arms). Primary endpoint: Event-Free Survival. Planned start Jun 2025; status: authorised.
02
Drugs
intismeran autogenebcg vaccine
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2024-517335-46-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517335-46-00.